Fact sheet updated November 2017

To improve the lives of patients by creating & developing innovative antibody products

2 marketed products
DARZALEX® marketed in the US, Europe & other countries
Arzerra® marketed globally

2 proprietary technologies
DuoBody® bispecific platform
HexaBody® technology

>20 pre-clinical projects
Extensive partnered & own pre-clinical pipeline

23 INDs
Investigational new drug applications filed by Genmab & partners in 17 years

9 products in clinical development by Genmab and its partners
Daratumumab & ofatumumab in late stage clinical development
Tisotumab vedotin & HuMax®-AXL-ADC in early stage clinical development

2 categories of cancer
Generate products to treat both solid tumors & hematological cancers

3 office locations
Facilities in Denmark, the Netherlands & USA

>200 FTE
Highly experienced & skilled employees

DKK
70.8B
2016 year end market cap

DKK
763M
2016 operating expenses
32% increase versus 2015

DKK
1,816M
2016 revenue
60% increase versus 2015

DKK
3,922M
2016 year end cash position

Operating Result
MDKK



2017 Guidance

Income Statement	DKKM	USDM*
Revenue	1,900 – 2,150	309 - 341
Operating expenses	(1,000) – (1,100)	(159) – (174)
Operating income	900 – 1,100	143 - 174
Cash position at end of year*	>4,500	>714

*Cash, cash equivalents, and marketable securities
USD 1.00 = DKK 6.3038

Our Three-pronged Strategy
Focus on core competence
Turn science into medicine
Build a profitable & successful biotech

Executive Management:

Jan G. J. van de Winkel
Ph.D. President & CEO

David A. Eatwell FCCA
Executive Vice President & CFO

Judith Klimovsky M.D.
Executive Vice President & CDO

Founded: 1999, IPO: 2000
Exchange: NASDAQ
OMX Copenhagen A/S

Symbol:
GEN

ADR ticker Symbol:

GMXAY

Stock information as of November 8, 2017:

Market cap:
~DKK 75 Bn (~USD 11,711 M)

Shares outstanding:
61,163,142

For more information: genmab.com or contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications (+45)33447720

Robust Product Pipeline and Passion for Innovation

Further Development for Marketed Products



Product		Disease Indications
Daratumumab Target: CD38, Partner: Janssen	BTD	Multiple myeloma (MM) Amyloidosis Natural Killer/T-Cell lymphoma (NKTCL), Nasal Type Myelodysplastic Syndromes (MDS) Solid tumors
Ofatumumab Target: CD20, Indication: Cancer Partner: Novartis		Follicular lymphoma (FL)
Ofatumumab (OMB157) Target: CD20, Indication: AI Partner: Novartis		Relapsing multiple sclerosis (RMS) (SubQ)

Antibody Powerhouse

Product		Disease Indications
Tisotumab vedotin Target: TF		Solid Cancers
HuMax-AXL-ADC Target: AXL		Solid Cancers
Teprotumumab (RV001) Target: IGF-1R Partner: River Vision	BTD	Graves' orbitopathy
AMG 714 Target: IL-15 Partner: Celimmune (sublicensed from Amgen)		Celiac Disease
ADCT-301 (HuMax-TAC-ADC) Target: CD25 Partner: ADCT		Lymphoma Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)
JNJ-61186372 Targets: EGFR, cMET Partner: Janssen		Non-small-cell lung cancer (NSCLC)
JNJ-63709178 Targets: CD3, CD123, Partner: Janssen		Acute Myeloid Leukemia (AML)
JNJ-64007957 Targets: BCMA, CD3 **Partner: Janssen**		Relapsed or refractory MM
> 20 Active Pre-clinical programs incl., HexaBody-DR5/DR5, DuoBody CD3xCD20		Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody Partnered programs: HuMab, DuoBody & HexaBody

At-A-Glance – SELECTED PRODUCTS

DARZALEX® (daratumumab)
- First-in-class CD38 antibody in dev. to treat cancer
- Marketed as monotherapy in US & EU for double refractory MM
- Approved in US, EU & Japan in combo w/ Revlimid & dex or Velcade & dex for relapsed/refractory MM
- Approved in US in combo w/ Pomalyst & dex for pts w/ MM who have received at least 2 prior therapies
- Studies ongoing for all stages of MM & in solid tumors
- Collaboration with Janssen
- 2016 net sales by Janssen were $572M

Tisotumab vedotin
- Antibody-drug conjugate (ADC, antibody coupled to a cell-killing agent) in dev. to treat solid tumors
- Ph II study in various solid tumors ongoing
- Ph II clinical study in cervical cancer announced
- License and collaboration with Seattle Genetics

HuMax®-AXL-ADC
- ADC in development to treat solid tumors
- Ph I/II clinical study for solid tumors ongoing

Arzerra ® (ofatumumab)
- Human CD20 antibody in dev. to treat cancer & autoimmune disease
- Approved in certain territories for certain CLL indications
- 2 Ph III studies w/ low dose subcutaneous in RMS ongoing
- Collaboration with Novartis
- 2016 net sales by Novartis were $46M

Pre-Clinical Programs
- Broad pre-clinical pipeline of >20 programs including HexaBody-DR5/DR5 & DuoBody-CD3xCD20
- Pre-clinical pipeline includes both partnered products & in-house programs based on our proprietary technologies
- Multiple INDs expected to be submitted over coming years

TECHNOLOGIES

DuoBody® Platform
- Genmab's proprietary bispecific antibody tech. platform
- Potential application in cancer, autoimmune, infectious, cardiovascular & CNS diseases
- Multiple ongoing collaborations incl. with Novartis, Novo Nordisk, Gilead & Janssen Biotech

HexaBody® Technology
- Genmab's proprietary enhanced potency antibody tech. platform
- Broadly applicable tech. builds on natural antibody biology
- Pre-clinical proof-of-concept achieved
- Multiple research collaborations

Antibody-Drug Conjugates
- Monoclonal antibodies w/ potent toxic agents coupled to them
- Expanding development area or cancer immunotherapy

Antibody Generation Technology Platforms
- UltiMab transgenic mouse technology
- OmniAb transgenic mouse & rat platforms
- MAB Discovery's rabbit antibody platform

Read more*
Products in development, Daratumumab, Ofatumumab, Tisotumab vedotin, HuMax-AXL-ADC, Pre-clinical programs, Technologies